NCAM1 and colorectal carcinoma: In contrast, a previous study in CRC showed that third-line treatment with the EGFR monoclonal antibody, cetuximab, was not shown to affect the frequency of CD56+ or CD56+ CD16+ cells in advanced CRC patients (41).